CRISPR-Cas9 genetic screens to ameliorate cellular stress in neurodegeneration
NOTE: REVISED DATE Dr. Emmanouil Metzakopian leads a team at the UK DRI in Cambridge. The aim of his projects is to identify genes which confer resistance to cellular stress (oxidative and ER) and involved in synaptic maintenance in dopamine neurons. He received his PhD in midbrain development from University College London under the supervision of Dr. Siew-Lan Ang at the National Institute for Medical Research. Emmanouil has been working on genome scale genetic screens in neurodegeneration using the CRISPR-Cas9 gene editing tool in collaboration with the Wellcome Trust Sanger Institute. He was involved in designing and producing the first human and mouse CRISPR arrayed library and received the R&D 100 award for this achievement. This library is now distributed by SIGMA.
Date: 9 February 2021, 13:00
Venue: ***REVISED DATE***. This seminar will be held online. Please email opdc.administrator@dpag.ox.ac.uk for more details.
Speaker: Dr. Emmanouil Metzakopian (UK Dementia Research Institute (UK DRI), University of Cambridge)
Organising department: Department of Physiology, Anatomy and Genetics (DPAG)
Organiser: Lorraine Dyson (University of Oxford)
Host: Professor Richard Wade-Martins (Professor of Molecular Neuroscience, University of Oxford)
Part of: OPDC Seminar Series (DPAG)
Booking required?: Not required
Audience: Members of the University only
Editor: Lorraine Dyson